This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Clinical research suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could increase efficacy.

CMRI researchers discovered that DNA repair pathways control how cancer cells die after radiotherapy. Blocking a key repair ...

Chinese scientists unveil breakthrough therapy that could save lives from nuclear fallout - Therapy may also help control ...

Johns Hopkins University School of Medicine researchers have discovered a dual regulatory mechanism safeguarding ...

Researchers at the University of Michigan have identified how mitochondrial dysfunction impairs insulin-producing pancreatic ...

Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent ...

Mitochondrial stress disrupts insulin production in diabetes, but reversing the damage may restore β-cell function.

Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent ...

Both Tabrizi and Yang think that knocking down MSH3 could stave off HD pathology. Tabrizi noted that MSH3 also modifies other run-on repeats, including those causing fragile X syndrome, myotonic ...

GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Eric Jonasch discussing a phase 1b/2 study of combination 177Lu girentuximab + cabozantinib and ...